NL-OMON43388已完成不适用
Trigeminovascular effects of propranolol in migraine treatment - TREPMI
Inwendige Geneeskunde0 个研究点目标入组 22 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age between 18 and 64 years
- •Non-smoking for more than 6 months
- •Females should use an oral contraceptive pill
- •Body mass index between 19 and 28 kg/m^2
- •Capable and willing to give informed consent
- •General good health, based on medical history and physical examination
排除标准
- •History of cardiovascular disease
- •History of migraine
- •Previous history of asthma or use of bronchodilators.
- •Blood pressure <110 systolic (sitting)
- •Heart rate <60 bpm
- •Perimenopausal status of females
- •Any serious illness that can compromise study participation
- •Use of any medication (e.g., NSAIDs, other analgesics) < 48 hrs before the study, as well as during the study.
- •Dermal diseases at the upper frontal side of the face
- •Pregnancy or breastfeeding
- •History of sensitivity to the fruits of capsicum plants (e.g. chilli peppers)
- •Alcohol or drug abuse
研究者
相似试验
已完成
2 期
eoadjuvant trial on the efficacy of propranolol monotherapy in angiosarcoma.angiosarcomasoft tissue cancer arising from the blood vessels10072990NL-OMON49514Antoni van Leeuwenhoek Ziekenhuis14
已完成
3 期
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral NeuropathyDiabetic Neuropathy, PainfulNCT01332149Pfizer's Upjohn has merged with Mylan to form Viatris Inc.626
已完成
不适用
Occipital nerve stimulation in patients with medically intractable chronic cluster headache: A PET study10019231cluster headacheNL-OMON39533eids Universitair Medisch Centrum24
已完成
不适用
Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant WomenCardiovascular DiseasesPregnancyMigraineNCT05854992Mayo Clinic68,419
已完成
2 期
Staccato Prochlorperazine in Migraine (Out Patient)Migraine HeadacheAuraNCT00422812Alexza Pharmaceuticals, Inc.400